Listing of Claims:

1-87. (Canceled)

88. (Previously Presented) A solid pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable carrier and 10 mg of oxandrolone per unit dosage form.

89. (Previously Presented) The solid pharmaceutical composition of claim 88 which comprises corn starch.

90. (Previously Presented) The solid pharmaceutical composition of claim 88 which comprises hydrous lactose.

91. (Previously Presented) The solid pharmaceutical composition of claim 88 which comprises hydroxypropyl methylcellulose.

92. (Previously Presented) The solid pharmaceutical composition of claim 88 which comprises magnesium stearate.

93. (Previously Presented) The solid pharmaceutical composition of claim 88 which is in the form of a daily dose.

94. (Previously Presented) A tablet comprising a pharmaceutically acceptable carrier and 10 mg of oxandrolone per tablet.

95. (Previously Presented) The tablet of claim 94 which comprises corn starch.

96. (Previously Presented) The tablet of claim 94 which comprises hydrous lactose.

97. (Previously Presented) The tablet of claim 94 which comprises hydroxypropyl methylcellulose.

98. (Previously Presented) The tablet of claim 94 which comprises magnesium stearate.

99. (Previously Presented) The tablet of claim 94 which is in the form of a daily dose.

100. (Previously Presented) A tablet comprising corn starch, hydrous lactose, hydroxypropyl methylcellulose, magnesium stearate, and 10 mg of oxandrolone per tablet.

101. (Previously Presented) The tablet of claim 100 which is in the form of a daily dose.

102. (Previously Presented) The tablet of claim 100, wherein the corn starch is present in an amount of 30 mg.

103. (Previously Presented) The tablet of claim 100, wherein the hydrous lactose is present in an amount of 113 mg.

104. (Previously Presented) The tablet of claim 100, wherein the hydroxypropyl methylcellulose is present in an amount of 3 mg.

105. (Previously Presented) The tablet of claim 100, wherein the magnesium stearate is present in an amount of 1.5 mg

106. (New) A method of ameliorating myopathy and muscle weakness in a patient infected with a Type-1 human immunodeficiency virus comprising administering to the subject the solid

pharmaceutical composition of claim 1 so as to thereby ameliorate the myopathy and muscle weakness in the patient.